We are live on ! Find out more
PVMCV

Polaris Venture Management Co V Portfolio holdings

AUM $14.1M
1-Year Est. Return 121.41%
This Fund
S&P 500
This Quarter Est. Return
+14.56%
1 Year Est. Return
+121.41%
3 Year Est. Return
+281.18%
5 Year Est. Return
+1,023.01%
10 Year Est. Return
–
AUM
$128M
AUM Growth
+$18M
Cap. Flow
-$17.2M
Cap. Flow %
-13.35%
Top 10 Hldgs %
100%
Holding
11
New
1
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
LYRA
LYRA THERAPEUTICS INC
LYRA
+$16.1M
2
ATYR
aTyr Pharma
ATYR
+$4

Top Sells

Rank Stock Value
1
KALA icon
KALA BIO
KALA
+$4.97M

Sector Composition

Rank Sector Weight
1 Healthcare 51.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
1
Fate Therapeutics
FATE
$286M
$39.1M 30.44%
1,139,783
– –
LYRA
2
DELISTED
LYRA THERAPEUTICS INC
LYRA
$12.5M 9.72%
+22,017
New +$16.1M
RNAC icon
3
Cartesian Therapeutics
RNAC
$229M
$7.88M 6.13%
92,449
– –
XFOR icon
4
X4 Pharmaceuticals
XFOR
$375M
$2.9M 2.26%
10,383
– –
STIM icon
5
Neuronetics
STIM
$138M
$1.41M 1.1%
732,583
– –
PULM icon
6
Pulmatrix
PULM
$6.35M
$618K 0.48%
17,972
– –
ATYR
7
aTyr Pharma
ATYR
$47.6M
$580K 0.45%
130,572
+1
+0% +$4
GNCA
8
DELISTED
Genocea Biosciences, Inc.
GNCA
$566K 0.44%
246,078
– –
DARE icon
9
Dare Bioscience
DARE
$18.3M
$323K 0.25%
27,187
– –
KALA icon
10
KALA BIO
KALA
$14.1M
– –
-226
Closed -$4.97M

Similar funds

IFC
Intact Financial Corporation Toronto, Ontario, Canada $14M AUM
AG
Ashmore Group London, United Kingdom $16.3M AUM 57.83% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
IR
Invictus RG Hamilton, Bermuda $8.9M AUM 56.32% 1-Year Est. Return
CCM
Copernicus Capital Management San Francisco, California $8.26M AUM 37.91% 1-Year Est. Return
EIP
Edgbaston Investment Partners $20.3M AUM 35.98% 1-Year Est. Return
AAM
Areion Asset Management Hong Kong $7.82M AUM 16% 1-Year Est. Return
OEP
Ocean Endowment Partners Chicago, Illinois $20.6M AUM 27.63% 1-Year Est. Return

Polaris Venture Management Co V's Q2 2020 Portfolio in Review

As of Q2 2020, Polaris Venture Management Co V held 11 positions worth $128M, up 16% from $110M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Polaris Venture Management Co V withdrew a net $17.2M in Q2 2020, closing 1 position and reducing 1 holding. Its most notable exit was KALA BIO, an estimated $4.97M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 39% a quarter earlier.

Against the trend, Polaris Venture Management Co V opened a new position in LYRA THERAPEUTICS INC worth $12.5M.

  • Polaris Venture Management Co V's largest Q2 2020 buy was LYRA THERAPEUTICS INC: 22,017 shares worth $12.5M.
  • Polaris Venture Management Co V added most to aTyr Pharma in Q2 2020, an estimated $4 increase.
  • Polaris Venture Management Co V fully exited KALA BIO in Q2 2020, selling an estimated $4.97M.
  • Polaris Venture Management Co V's ten largest holdings make up 100% of its $128M portfolio in Q2 2020.
  • Polaris Venture Management Co V opened 1 new position and closed 1 in Q2 2020.
  • Polaris Venture Management Co V's portfolio value rose 16% quarter-over-quarter to $128M.

Based on Polaris Venture Management Co V's 13F filing for Q2 2020, filed 12 Aug 2020.